Tags

Type your tag names separated by a space and hit enter

TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
J Thromb Haemost 2005; 3(7):1503-10JT

Abstract

OBJECTIVES

To evaluate the association of thrombin-activatable fibrinolysis inhibitor (TAFI) gene polymorphisms with the risk of coronary heart disease (CHD) and with TAFI levels measured by a newly developed enzyme-linked immunosorbent assay (ELISA) (TAFI-1B1), shown to be a reliable method for detecting quantitative variations in circulating TAFI.

PATIENTS/METHODS

Six polymorphisms (C-2599G, G-438A, Ala147Thr, Thr325Ile, C + 1542G and T + 1583A) were genotyped and baseline plasma concentrations of TAFI were measured in a nested case-control design as part of the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Participants from France and Northern Ireland who had developed a CHD event during a 5-year follow-up (n = 321) were compared with 645 population- and age-matched control subjects.

RESULTS

In France, the Thr147 allele was more frequent in cases than in controls (0.41 vs. 0.32; P = 0.02), whereas the reverse was observed in Northern Ireland (0.33 vs. 0.38; P = 0.19) (P = 0.01 for interaction). No other polymorphism was associated with CHD risk. Consistent with the results derived from the single-locus analysis, haplotype analysis revealed that the haplotype carrying the Thr147 allele was associated with increased risk of CHD in France while the reverse tended to hold in the Northern Ireland population. Single-locus and haplotype analyses revealed that two polymorphisms, C-2599G and Ala147Thr (or T + 1583A that is in nearly complete association with it), had additive effects on TAFI levels and explained >18% of TAFI variability. This effect was homogeneous in France and Northern Ireland, and in cases and controls who exhibited similar TAFI levels.

CONCLUSIONS

Thrombin-activatable fibrinolysis inhibitor gene polymorphisms are strongly associated to plasma TAFI levels, but the relation to CHD risk is less clear.

Authors+Show Affiliations

INSERM U626, Hematology Laboratory, Faculty of Medicine, CHU Timone, Marseille, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15978108

Citation

Morange, P E., et al. "TAFI Gene Haplotypes, TAFI Plasma Levels and Future Risk of Coronary Heart Disease: the PRIME Study." Journal of Thrombosis and Haemostasis : JTH, vol. 3, no. 7, 2005, pp. 1503-10.
Morange PE, Tregouet DA, Frere C, et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost. 2005;3(7):1503-10.
Morange, P. E., Tregouet, D. A., Frere, C., Luc, G., Arveiler, D., Ferrieres, J., ... Juhan-Vague, I. (2005). TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. Journal of Thrombosis and Haemostasis : JTH, 3(7), pp. 1503-10.
Morange PE, et al. TAFI Gene Haplotypes, TAFI Plasma Levels and Future Risk of Coronary Heart Disease: the PRIME Study. J Thromb Haemost. 2005;3(7):1503-10. PubMed PMID: 15978108.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. AU - Morange,P E, AU - Tregouet,D A, AU - Frere,C, AU - Luc,G, AU - Arveiler,D, AU - Ferrieres,J, AU - Amouyel,P, AU - Evans,A, AU - Ducimetiere,P, AU - Cambien,F, AU - Tiret,L, AU - Juhan-Vague,I, AU - ,, PY - 2005/6/28/pubmed PY - 2005/9/28/medline PY - 2005/6/28/entrez SP - 1503 EP - 10 JF - Journal of thrombosis and haemostasis : JTH JO - J. Thromb. Haemost. VL - 3 IS - 7 N2 - OBJECTIVES: To evaluate the association of thrombin-activatable fibrinolysis inhibitor (TAFI) gene polymorphisms with the risk of coronary heart disease (CHD) and with TAFI levels measured by a newly developed enzyme-linked immunosorbent assay (ELISA) (TAFI-1B1), shown to be a reliable method for detecting quantitative variations in circulating TAFI. PATIENTS/METHODS: Six polymorphisms (C-2599G, G-438A, Ala147Thr, Thr325Ile, C + 1542G and T + 1583A) were genotyped and baseline plasma concentrations of TAFI were measured in a nested case-control design as part of the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Participants from France and Northern Ireland who had developed a CHD event during a 5-year follow-up (n = 321) were compared with 645 population- and age-matched control subjects. RESULTS: In France, the Thr147 allele was more frequent in cases than in controls (0.41 vs. 0.32; P = 0.02), whereas the reverse was observed in Northern Ireland (0.33 vs. 0.38; P = 0.19) (P = 0.01 for interaction). No other polymorphism was associated with CHD risk. Consistent with the results derived from the single-locus analysis, haplotype analysis revealed that the haplotype carrying the Thr147 allele was associated with increased risk of CHD in France while the reverse tended to hold in the Northern Ireland population. Single-locus and haplotype analyses revealed that two polymorphisms, C-2599G and Ala147Thr (or T + 1583A that is in nearly complete association with it), had additive effects on TAFI levels and explained >18% of TAFI variability. This effect was homogeneous in France and Northern Ireland, and in cases and controls who exhibited similar TAFI levels. CONCLUSIONS: Thrombin-activatable fibrinolysis inhibitor gene polymorphisms are strongly associated to plasma TAFI levels, but the relation to CHD risk is less clear. SN - 1538-7933 UR - https://www.unboundmedicine.com/medline/citation/15978108/TAFI_gene_haplotypes_TAFI_plasma_levels_and_future_risk_of_coronary_heart_disease:_the_PRIME_Study_ L2 - https://doi.org/10.1111/j.1538-7836.2005.01486.x DB - PRIME DP - Unbound Medicine ER -